First RSV Vaccine Approved for Older Adults Amid Rising Infections

Australia's TGA approves GSK's Arexvy, shown to reduce RSV illness by over 80% in first season, as healthcare systems grapple with increased strain.

RSV infections are posing a significant health risk to older adults, particularly those with pre-existing medical conditions, leading to increased strain on healthcare systems.
Australia's Therapeutic Goods Administration (TGA) has approved the first-ever RSV vaccine, Arexvy, manufactured by GSK, for adults over 60.
Arexvy has been shown to reduce illness from RSV by more than 80% in the first season after vaccination.
Despite the development of a new RSV vaccine for children under 5, families and doctors continue to face access issues.
Other RSV vaccines are in development, including ones from Pfizer and Moderna, and strategies to protect the youngest age group from the virus are being explored.